TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Ox-1 Investor Presentation

Alderley Park, 10 June 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, will be hosting a webinar for investors at 11.30am BST, on Wednesday 11 June 2025.

It will provide an in-depth look at the Ox-1 addiction programme. The session will be led by TheraCryf's CBO, Dr Helen Kuhlman, together with neuroscientist and consultant to the Company, Dr Fraser Murray. Access to the session is open to all existing and potential shareholders via the Investor Meet Company platform.

Investors who already follow TheraCryf plc on the Investor Meet Company platform have automatically been invited. New registrants can sign up to Investor Meet Company for free HERE.

-Ends-

Enquiries

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma** and neurodevelopmental disorders [**orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.